MSB 1.22% $2.43 mesoblast limited

Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-441

  1. 2,325 Posts.
    lightbulb Created with Sketch. 474
    Yes that's correct but I also have read a lot about them over the last two+ years. And whilst having a laugh at their expense, I learnt more.

    There is a chance that CYP will fly, IMO. Not enough that I have bought shares in CYP but I'm happy to know about them and things from here on in are going to move more quickly I reckon so who knows!

    FYI, ddwn is a shareholder of CYP. Take that as a positive or a negative, ha ha ha. You may think I'm joking that ddwn is a shareholder, but I'm not.

    Friday's news was a massive blow to CYP. MSB going down the path of 3D manufacturing in earnest, backed by Novartis has punched a massive hole in their 'look at me, quick' pitch. They still have their Phase III Osteo Arthritis trial that starts next year which is very interesting but will be 2.5 years away from completion and is under the MSB IP cloud (IMO).

    CYP could be on someone's radar to purchase but yesterday's news makes the whole game different.
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Mkt cap ! $1.427B
Open High Low Value Volume
$2.46 $2.49 $2.42 $6.626M 2.708M

Buyers (Bids)

No. Vol. Price($)
22 86127 $2.43

Sellers (Offers)

Price($) Vol. No.
$2.44 8155 2
View Market Depth
Last trade - 16.10pm 22/01/2021 (20 minute delay) ?
-0.030 ( 1.05 %)
Open High Low Volume
$2.48 $2.48 $2.42 1054431
Last updated 15.59pm 22/01/2021 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.